{"nctId":"NCT03329846","briefTitle":"An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma","startDateStruct":{"date":"2017-11-30","type":"ACTUAL"},"conditions":["Melanoma","Skin Cancer"],"count":20,"armGroups":[{"label":"Nivolumab + Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Nivolumab","Drug: Placebo"]},{"label":"Nivolumab + BMS-986205","type":"EXPERIMENTAL","interventionNames":["Drug: BMS-986205","Biological: Nivolumab"]}],"interventions":[{"name":"BMS-986205","otherNames":[]},{"name":"Nivolumab","otherNames":["BMS-936558"]},{"name":"Placebo","otherNames":["BMS-986205 matching placebo"]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* 12 years and older unless not permitted by local regulations; in that case 18 years old and older\n* Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1\n* Histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) Staging Manual (8th edition)\n* Treatment-na√Øve participants (no prior systemic anticancer therapy for unresectable or metastatic melanoma)\n* Measurable disease per RECIST v1.1\n\nExclusion Criteria:\n\n* Active brain metastases or leptomeningeal metastases\n* Uveal or ocular melanoma\n* Participants with active, known, or suspected autoimmune disease\n* Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured\n\nOther protocol defined inclusion/exclusion criteria could apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Experiencing Adverse Events","description":"Number of participants experiencing different types of Adverse Events, including Death, Any cause Adverse Events (AEs), Drug-related AEs, Any cause Serious Adverse Events (SAEs), Drug-related SAEs, SAEs leading to discontinuation, and Drug-related Non-serious AEs leading to discontinuation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":10},"commonTop":["Nausea","Asthenia","Decreased appetite","Arthralgia","Fatigue"]}}}